Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of the National Cancer Institute

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djt072PMID 23594426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

  2012cited by this paper
• TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

  2012cited by this paper
• Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.

  2012cited by this paper
• Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

  2012cited by this paper
• Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

  2012cited by this paper
• Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

  2012cited by this paper
• Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  2012cited by this paper
• Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

  2012cited by this paper
• Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

  2012cited by this paper
• Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials

  2012cited by this paper
• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

  2012cited by this paper
• Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

  2012cited by this paper
• Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

  2012cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

  2011cited by this paper
• Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review

  2011cited by this paper
• Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

  2011cited by this paper
• Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group.

  2010cited by this paper
• Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

  2010cited by this paper
• TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy.

  2010cited by this paper
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Issues in using progression-free survival when evaluating oncology products.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

  2008cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Lung cancer in never smokers — a different disease

  2007cited by this paper
• Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

  2007cited by this paper
• A Translational View of the Molecular Pathogenesis of Lung Cancer

  2007cited by this paper
• Standard versus adaptive monitoring procedures: a commentary

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

  2005cited by this paper
• EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper

• HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer

  2026cites this paper
• Handling Missing Modalities in Multimodal Survival Prediction for Non-Small Cell Lung Cancer

  2026cites this paper
• Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital

  2025cites this paper
• Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China

  2025cites this paper
• ID-CRISPR: A CRISPR/Cas12a platform for label-free and sensitive detection of rare mutant alleles using self-interference DNA hydrogel reporter.

  2025cites this paper
• Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study

  2025influential citation
• Next generation DNA sequencing data analysis and its application in clinical genomics.

  2025cites this paper
• Investigation of Epidermal Growth Factor Receptor Pathway Related, Exosomal miRNAs in Non-Small Cell Lung Cancer Cases

  2025cites this paper
• The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study

  2024cites this paper
• T790M mutation sensitizes non-small cell lung cancer cells to radiation via suppressing SPOCK1

  2024cites this paper
• First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors.

  2024cites this paper
• Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.

  2024cites this paper
• Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

  2024cites this paper
• Clinical results and hematological predictors of linac-based stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastasis in patients aged 75 years or higher: a retrospective study.

  2024cites this paper
• EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.

  2024cites this paper
• Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression

  2024cites this paper
• Prevalence of epidermal growth factor receptor (EGFR) mutations and correlation with histological patterns in lung adenocarcinoma in patients from Bosnia and Herzegovina.

  2024cites this paper
• Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

  2024cites this paper
• The therapeutic potential of RNA m(6)A in lung cancer

  2024cites this paper
• Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT.

  2023cites this paper
• Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors

  2023cites this paper
• Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland.

  2023cites this paper
• Challenges in the Management of Lung Adenocarcinoma in Elderly Patients: Case Report

  2023cites this paper
• Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?

  2023cites this paper
• A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer

  2023cites this paper
• Chorioallantoic membrane assay revealed the role of TIPARP (2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly (ADP-ribose) polymerase) in lung adenocarcinoma-induced angiogenesis

  2023cites this paper
• Inhibition of miR‐578 through SOCS2‐dependent manner reverses gefitinib resistance in NSCLC cells

  2023cites this paper
• Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations

  2023influential citation
• EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

  2023influential citation
• Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

  2022cites this paper
• Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non–Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience

  2022cites this paper
• Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine

  2022cites this paper
• Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment

  2022cites this paper
• Which scoring system is the most accurate for assessing survival prognosis in patients undergoing surgery for spinal metastases from lung cancer? A single-center experience.

  2022cites this paper
• The Anticancer Effect of Metformin Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

  2022cites this paper
• Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer

  2022cites this paper
• XÁC ĐỊNH ĐỘT BIẾN GEN EGFR VÀ ĐỘT BIẾN DUNG HỢP GEN EML4-ALK Ở BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ

  2022influential citation
• Complex Germline K757N Mutation in Non-Small-Cell Lung Cancer: A Case Report

  2022cites this paper
• Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases

  2022cites this paper
• Multifunctional Oxygenated Particles for Targeted Cancer Drug Delivery and Evaluation with Darkfield Hyperspectral Imaging

  2022cites this paper
• Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib

  2022cites this paper
• Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression

  2022cites this paper
• EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain

  2022cites this paper
• Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).

  2022cites this paper
• Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells

  2022cites this paper
• Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

  2022cites this paper
• Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.

  2022cites this paper
• The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients

  2022cites this paper
• Identification of the structural features of quinazoline derivatives as EGFR inhibitors using 3D-QSAR modeling, molecular docking, molecular dynamics simulations and free energy calculations

  2021cites this paper
• Đánh giá kết quả thuốc Erlotinib trong điều trị bước một ung thư phổi không tế bào nhỏ có đột biến EGFR

  2021cites this paper
• Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

  2021cites this paper
• Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects.

  2021cites this paper
• Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2021cites this paper
• The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up

  2021influential citation
• First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

  2021cites this paper
• Carcinoma de pulmón no microcítico

  2021cites this paper
• Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement

  2021cites this paper
• Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S.

  2021cites this paper
• Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.

  2021cites this paper
• Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively

  2021cites this paper
• First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence

  2021cites this paper
• Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.

  2021cites this paper
• EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis

  2021cites this paper
• Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.

  2021cites this paper
• Current Management of Vertebral Metastases: Teamwork Manejo actual de las metástasis vertebrales: un trabajo en equipo

  2021cites this paper
• Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

  2021cites this paper
• Manejo actual de las metástasis vertebrales: un trabajo en equipo Current Management of Vertebral Metastases: Teamwork

  2021cites this paper
• A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).

  2021cites this paper
• Adequacy of samples obtained via percutaneous core-needle rebiopsy for EGFR T790M molecular analysis in patients with non-small cell lung cancer following acquired resistance to first-line therapy: A systematic review and meta-analysis.

  2021cites this paper
• Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada

  2021cites this paper
• Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment.

  2021cites this paper
• 肺癌による転移性骨腫瘍の組織型別の発生時期，部位，予後に関する臨床研究

  2021cites this paper
• Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.

  2020cites this paper
• Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer

  2020cites this paper
• Nivolumab Monotherapy or Combination Therapy with Ipilimumab for Lung Cancer: A meta-analysis of Randomized Controlled Trials

  2020cites this paper
• Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives

  2020cites this paper
• Circulating Tumour Cells in Lung Cancer.

  2020cites this paper
• Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

  2020cites this paper
• Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations

  2020cites this paper
• Targeting lung cancer using advanced drug delivery systems

  2020cites this paper
• Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation

  2020cites this paper
• Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.

  2020cites this paper
• Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma

  2020cites this paper
• Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

  2020cites this paper
• DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer

  2020cites this paper
• Genomic Strategies for Personalized Cancer Therapy

  2020cites this paper
• Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.

  2020cites this paper
• Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.

  2020cites this paper
• Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status.

  2020cites this paper
• Perfil molecular tumoral del cáncer pulmonar medido por secuenciación de nueva generación

  2020cites this paper
• Dynamic Changes of EGFR Activating Mutations as an Early Predictor of Progression in Non–Small Cell Lung Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors

  2020cites this paper
• Long term follow-up of EGFR mutated NSCLC cases

  2020cites this paper
• Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis

  2020cites this paper
• Implications of lipid droplets in lung cancer: Associations with drug resistance

  2020cites this paper
• Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

  2020cites this paper
• Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review

  2020cites this paper
• Targeted Therapy for Non-Small Cell Lung Cancer

  2020cites this paper
• Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2020cites this paper